Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Arthritis Res Ther. 2020 Jun 23;22(1):155. doi: 10.1186/s13075-020-02247-3.

¹ Keio University School of Medicine, Tokyo, Japan. tsutake@z5.keio.jp.
² University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
³ University of Tokyo, Tokyo, Japan.
⁴ Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
⁵ Seoul National University, Seoul National University Hospital, Seoul, South Korea.
⁶ Taichung Veterans General Hospital, Taichung, Taiwan.
⁷ Astellas Pharma, Inc., Tokyo, Japan.

Abstract

An amendment to this paper has been published and can be accessed via the original article.